Dermatology Research and Treatment Development
In-depth dermatology clinical development experience
With the PPD clinical research business of Thermo Fisher Scientific as your CRO, you gain a dermatology partner with deep therapeutic insight, strong global site relationships, patient-centric strategies to reach diverse skin health populations, and industry-leading endpoint data expertise.
Ready to drive successful study execution?
Expert support at every stage of the process
Empower your dermatology program with a truly integrated development solution. Sponsors worldwide turn to us for comprehensive expertise that spans every step of the journey—strategic consultancy, pre-clinical planning, analytical and regulatory guidance, and clinical development excellence. With a track record of supporting successful MAA, NDA, and BLA submissions across international markets, we help transform promising science into approved therapies.
Over the past five years, sponsors have leveraged our expertise to move dermatology drug development programs forward.
Dermatology trials
Enrolled patients
Investigator partners
Broad indication expertise in dermatology clinical studies
We continue to expand our areas of expertise to ensure sponsors receive the highest quality and most efficient clinical study design, management, and operations. Our comprehensive dermatology experience spans a broad range of indications including:
- Atopic Dermatitis
- Psoriasis
- Hidradenitis suppurativa
- Alopecia
- Pruritus & Prurigo Nodularis
- Chronic Urticaria (CSU and CIndU)
- Pemphigus vulgaris
- Bollus Pemphigoid
- Epidermolysis bullosa
- Dermatomyositis
- Cutaneous Lupus
- Aesthetics
Along with multiple other rare skin manifestations….
We enable rapid enrollment by forging relationships with high-performing sites and implementing new ways to overcome seasonal changes in individual countries by leveraging sites in both the Northern and Southern hemispheres — enabling participants to enroll continuously.
Expanding patient access to dermatology clinical trials
Sponsors complete dermatology studies rapidly and successfully with the support of our:
- Extensive expertise in dermatology clinical trials
- International network of sites experienced in key indications like psoriasis, atopic dermatitis, chronic urticaria and HS
- Access to a large database of potential trial participants
- Commitment to tailored trial design
Through our partnerships with Trialmed and Dermatology Site Networks, we enable sponsors to meet start-up timelines and enrollment metrics.
Our dermatology team has established strong connections with many patient advocacy groups (PAGs) active in dermatology diseases, which aids in the successful execution of patient-centric clinical trials.
Successful rapid startup of a psoriasis clinical trial
Discover how our dermatology experts overcame challenges in a Phase II psoriasis clinical trial.
Unlock transformative insights with PPD CorEvitas Dermatology Registries
Answer critical research questions with deeper insights to drive the development of innovative therapies with proprietary longitudinal data from our PPD™ CorEvitas™ Dermatology Registries. Our unique clinical registries capture robust, prospective regulatory-grade clinician- and patient-reported outcomes data on the health status of patients and the care and treatments they receive.
Access comprehensive real-world data sets to:
- Analyze patterns in treatments and outcomes
- Discover unmet need
- Provide safety and comparative effectiveness intelligence to inform decision-making, best practices and treatment decisions
Adult CorEvitas Dermatology Registries
- Psoriasis Registry
- Atopic Dermatitis Registry
- Alopecia Areata Registry
- Generalized Pustular Psoriasis Registry
Adolescent CorEvitas Dermatology Registries
- Adolescent Alopecia Areata Registry (International)
- Adolescent Atopic Dermatitis Registry (International)
Our dermatology clinical research experience
A deep understanding of the challenges of dermatology drug development fuels our support of customers spanning biopharmaceutical, biotech, medical device and academic organizations. Our global network of dedicated board-certified dermatologists, highly experienced clinical and operational professionals, and a range of investigator sites enables us to support trials for organizations of all sizes and across a myriad indications.
In the past five years, our dermatology team has performed trials for 32 pharmaceutical and biotech companies across all regions, including North America, South America, Europe and Asia-Pacific.
Patient first digital solutions in dermatology trials
Our patient first digital solutions center of excellence (COE) is dedicated to supporting patient recruitment and retention through digitally enabled diverse and sustainable clinical trials. We partner with this COE to revolutionize clinical research participation by breaking down traditional barriers and infusing innovation to expedite drug development for our clients. This partnership enhances our digital and decentralized solutions with unique dermatological expertise, providing a distinct edge for sponsors.
Dermatology studies managed:
Leading the way in dermatological research innovation
Unique scales managed:
Delivering precision and excellence in every measurement
Overall studies with DIM:
Demonstrating extensive experience and expertise
Manage the scientific risks in dermatology trials
While clinical trials in dermatology are not substantially different from those in other areas of medicine, they do have certain distinguishing features. These include development of drugs for topical use (in addition to systemic ones) where the vehicle effect can raise the placebo rates to levels higher than in other specialties. This makes the need for high-quality clinical data in dermatology trials essential.
When traditional monitoring methods may be insufficient, the implementation of advanced statistical monitoring techniques — known as scientific surveillance — is necessary for identifying data quality risks within centralized monitoring frameworks.
Scientific surveillance has three primary objectives:
- Detecting inconsistencies in scientific data
- Predicting risks
- Identifying inflated placebo response
Meet our dermatology medical directors
Sophia Tono, M.D.
medical director, dermatology pharmacovigilance
Maria Marcano Bozo
medical director, pharmacovigilance and medical science services
Wedad Abdelrahman, M.D.
associate medical director, pharmacovigilance
Craig Boyle, D.O., FACEP
vice president, medical operations, Trialmed Site Network
Dermatologic conditions are a leading cause of disability worldwide. It’s an exciting time in dermatology product development where unmet medical needs in psoriasis, atopic dermatitis and other diseases can be addressed with novel molecules, monoclonal antibodies, Janus kinase inhibitors (JAK) and other products that work across the inflammatory pathway.